Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Recent & Breaking News (TSXV:CLAS.H)

IIROC Trading Halt - CLAS

Canada NewsWire July 20, 2022

Claritas Pharmaceuticals (TSXV:CLAS) approved to list on the OTCQB

John Ballem  April 7, 2022

Claritas Announces Approval from OTC to Up-List to OTCQB

GlobeNewswire April 7, 2022

Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

GlobeNewswire April 5, 2022

Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company's Phase 1 Clinical Study of R-107 and Closing of Financing

GlobeNewswire February 22, 2022

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

GlobeNewswire February 9, 2022

Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

GlobeNewswire January 26, 2022

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

GlobeNewswire January 17, 2022

Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

GlobeNewswire January 17, 2022

Claritas (TSXV:CLAS) secures $5 million financing with Alumina Partners

Caroline Egan  January 12, 2022

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

GlobeNewswire January 12, 2022

Claritas (TSXV:CLAS) outlines development strategy for R-107

Julia Kennedy  January 4, 2022

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

GlobeNewswire January 4, 2022

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

GlobeNewswire December 22, 2021

Claritas (TSXV:CLAS) acquires license to develop and commercialize R-107

Caroline Egan  December 21, 2021

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

GlobeNewswire December 21, 2021

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

GlobeNewswire December 20, 2021

Claritas Provides Update Regarding Phase 1 Clinical Study

GlobeNewswire November 18, 2021

Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company's Planned Up-Listing of its Securities to the OTCQB

GlobeNewswire November 4, 2021

Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

GlobeNewswire October 19, 2021